RetinalGenix Technologies Inc. (RTGN) Financial Statements (2024 and earlier)

Company Profile

Business Address 1450 NORTH MCDOWELL BOULEVARD
PETALUMA, CA 94954
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 384,947
Cash and cash equivalents 384,947
Total current assets: 384,947
Noncurrent Assets
Property, plant and equipment156256 
Deferred costs   70,974
Other undisclosed noncurrent assets   (70,974)
Total noncurrent assets:156256 
TOTAL ASSETS:1562944,947
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:884,920475,480253,901
Interest and dividends payable2,619
Accounts payable   251,282
Accrued liabilities11,5997,759 
Other undisclosed accounts payable and accrued liabilities873,321467,721 
Debt49,00049,00073,000
Due to related parties537,118142,721
Total current liabilities:933,9201,061,598469,622
Noncurrent Liabilities
Other undisclosed liabilities471,8937,759 
Total liabilities:1,405,8131,069,357469,622
Equity
Equity, attributable to parent(1,405,657)(1,069,063)(464,675)
Common stock1,8191,7831,423
Additional paid in capital9,701,7197,947,4604,638,218
Accumulated deficit(11,109,195)(9,018,306)(5,104,316)
Total equity:(1,405,657)(1,069,063)(464,675)
TOTAL LIABILITIES AND EQUITY:1562944,947

Income Statement (P&L) (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Operating expenses(2,087,049)(3,908,850)(2,176,675)
Operating loss:(2,087,049)(4,361,897)(2,980,672)
Interest and debt expense(3,840)(5,140)(2,619)
Loss from continuing operations:(2,090,889)(4,367,037)(2,983,291)
Loss before gain (loss) on sale of properties:(2,983,291)
Net loss:(2,090,889)(4,367,037)(2,983,291)
Other undisclosed net income attributable to parent  453,047803,997
Net loss available to common stockholders, diluted:(2,090,889)(3,913,990)(2,179,294)

Comprehensive Income (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Net loss:(2,090,889)(4,367,037)(2,983,291)
Comprehensive loss, net of tax, attributable to parent:(2,090,889)(4,367,037)(2,983,291)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: